Osemitamab Completed Phase 2 Trials for Biliary Tract Neoplasms Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05190575TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer